TY - JOUR
T1 - Hyperplastic perilobar nephroblastomatosis
T2 - Long-term survival of 52 patients
AU - Perlman, Elizabeth J.
AU - Faria, Paulo
AU - Soares, Andreia
AU - Hoffer, Fred
AU - Sredni, Simone
AU - Ritchey, Michael
AU - Shamberger, Robert C.
AU - Green, Daniel
AU - Beckwith, J. B.
PY - 2006/2
Y1 - 2006/2
N2 - Background. This study provides insight into the clinical behavior, diagnostic complexities, and long-term management of patients with hyperplastic perilobar nephroblastomatosis (HPLN). Procedure. Fifty-two patients with HPLN with available long-term follow-up were retrospectively analyzed for pathologic, radiologic, and clinical features. Results. The mean age at diagnosis was 16 months; the lesions were bilateral in 49 patients. Of 33 patients who initially underwent diagnostic biopsy and adjuvant chemotherapy, 18 (55%) developed Wilms tumor (WT) at a mean of 35 months from diagnosis. Of 16 patients whose initial therapy included nephrectomy and adjuvant therapy, three (19%) developed WT at a mean of 36 months from diagnosis. All three patients who underwent initial diagnostic biopsy and received no adjuvant therapy during their initial course developed WT 4, 4, and 10 months following diagnosis. 24/52 patients developed either a single (13 patients) or multiple (11 patients) WT throughout their course; 8/24 (33%) of WT were anaplastic. The time from initial diagnosis to the development of the last WT ranged from 13 to 116 months (mean 42 months). Three children with HPLN died of WT at 3, 5, and 6 years of age; 2/3 were anaplastic. Conclusions. HPLN is a self-limited, pre-neoplastic proliferative process associated with a high risk of developing WT. The accurate diagnosis and the choices of therapy during the often-complex course of HPLN depend on the availability and accurate interpretation of a combination of pathologic, radiologic, and clinical information. When such information is appropriately obtained, the long-term survival of patients with HPLN is excellent.
AB - Background. This study provides insight into the clinical behavior, diagnostic complexities, and long-term management of patients with hyperplastic perilobar nephroblastomatosis (HPLN). Procedure. Fifty-two patients with HPLN with available long-term follow-up were retrospectively analyzed for pathologic, radiologic, and clinical features. Results. The mean age at diagnosis was 16 months; the lesions were bilateral in 49 patients. Of 33 patients who initially underwent diagnostic biopsy and adjuvant chemotherapy, 18 (55%) developed Wilms tumor (WT) at a mean of 35 months from diagnosis. Of 16 patients whose initial therapy included nephrectomy and adjuvant therapy, three (19%) developed WT at a mean of 36 months from diagnosis. All three patients who underwent initial diagnostic biopsy and received no adjuvant therapy during their initial course developed WT 4, 4, and 10 months following diagnosis. 24/52 patients developed either a single (13 patients) or multiple (11 patients) WT throughout their course; 8/24 (33%) of WT were anaplastic. The time from initial diagnosis to the development of the last WT ranged from 13 to 116 months (mean 42 months). Three children with HPLN died of WT at 3, 5, and 6 years of age; 2/3 were anaplastic. Conclusions. HPLN is a self-limited, pre-neoplastic proliferative process associated with a high risk of developing WT. The accurate diagnosis and the choices of therapy during the often-complex course of HPLN depend on the availability and accurate interpretation of a combination of pathologic, radiologic, and clinical information. When such information is appropriately obtained, the long-term survival of patients with HPLN is excellent.
KW - Nephroblastoma
KW - Nephroblastomatosis
KW - Perilobar nephrogenic rest
KW - Wilms tumor
UR - http://www.scopus.com/inward/record.url?scp=30444446496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30444446496&partnerID=8YFLogxK
U2 - 10.1002/pbc.20386
DO - 10.1002/pbc.20386
M3 - Article
C2 - 15816029
AN - SCOPUS:30444446496
SN - 1545-5009
VL - 46
SP - 203
EP - 221
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 2
ER -